BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Baumgart DC, le Claire M. The Expenditures for Academic Inpatient Care of Inflammatory Bowel Disease Patients Are Almost Double Compared with Average Academic Gastroenterology and Hepatology Cases and Not Fully Recovered by Diagnosis-Related Group (DRG) Proceeds. PLoS One 2016;11:e0147364. [PMID: 26784027 DOI: 10.1371/journal.pone.0147364] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Roggenbuck D, Reinhold D, Baumgart D, Schierack P, Conrad K, Laass M. Autoimmunity in Crohn's Disease—A Putative Stratification Factor of the Clinical Phenotype. Elsevier; 2016. pp. 77-101. [DOI: 10.1016/bs.acc.2016.06.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
2 White JR, Din S, Ingram RJM, Foley S, Alam MA, Robinson R, Francis R, Tucker E, Jalal M, Elphick D, Atallah E, Norman A, Amin M, Sajjad A, Heggs N, Meadowcroft S, Moran GW. Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK – a retrospective observational study. Scandinavian Journal of Gastroenterology 2020;55:907-16. [DOI: 10.1080/00365521.2020.1790647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 von Bremen J, Streckbein EM, Ruf S. Changes in university orthodontic care over a period of 20 years: Patient characteristics, treatment quality, and treatment costs. J Orofac Orthop 2017;78:321-9. [DOI: 10.1007/s00056-017-0088-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Schnorbach MT, Kruis W. [Cost of illness of inflammatory bowel disease in Germany]. Z Gastroenterol 2021;59:1173-88. [PMID: 32869213 DOI: 10.1055/a-1174-0670] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Einarson TR, Bereza BG, Tedouri F, Van Impe K, Denee TR, Dries PJT. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. Journal of Medical Economics 2017;20:1187-99. [DOI: 10.1080/13696998.2017.1363050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? Front Pharmacol 2019;10:279. [PMID: 30983996 DOI: 10.3389/fphar.2019.00279] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 14.7] [Reference Citation Analysis]
7 Stein J, Haas JS, Ong SH, Borchert K, Hardt T, Lechat E, Nip K, Foerster D, Braun S, Baumgart DC. Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany - a real-world evidence analysis. Clinicoecon Outcomes Res 2018;10:93-103. [PMID: 29440920 DOI: 10.2147/CEOR.S150900] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
8 Baumgart DC, Bokemeyer B, Drabik A, Stallmach A, Schreiber S; Vedolizumab Germany Consortium. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43:1090-1102. [PMID: 27038247 DOI: 10.1111/apt.13594] [Cited by in Crossref: 110] [Cited by in F6Publishing: 104] [Article Influence: 18.3] [Reference Citation Analysis]
9 Ciccocioppo R, Baumgart DC, Dos Santos CC, Galipeau J, Klersy C, Orlando G. Perspectives of the International Society for Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi). Cytotherapy 2019;21:824-39. [PMID: 31201092 DOI: 10.1016/j.jcyt.2019.05.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]